

Hokkaido Institute of Public Health  
N-19, W-12, Kita-ku, Sapporo,  
060, Japan

Faculty of Pharmaceutical Sciences,  
Kyushu University  
3-1-1 Maidashi, Higashi-ku  
Fukuoka, 812, Japan

MAKOTO NISHIZAWA  
TAKASHI YAMAGISHI

GEN-ICHIRO NONAKA  
ITSUO NISHIOKA

Received July 7, 1980

[Chem. Pharm. Bull.]  
[28(9)2852-2854(1980)]

### Synthesis of (23*R*)-Caldiol Lactone (25-Hydroxyvitamin D<sub>3</sub> 26,23-Lactone)<sup>1)</sup>

(23*R*)-Caldiol lactone(25-hydroxyvitamin D<sub>3</sub> 26,23-lactone) was synthesized from bisnorcholeonic acid. The configuration at C-23 was determined by transformation to 22- and 23-hydroxycholesterols.

**Keywords**—caldiol lactone; 25-hydroxyvitamin D<sub>3</sub> 26,23-lactone; metabolite of vitamin D<sub>3</sub>; 22-hydroxycholesterol; 23-hydroxycholesterol

Caldiol lactone<sup>2)</sup> is a new metabolite of Vitamin D<sub>3</sub>. Although the preliminary tests of this metabolite showed interesting biological activity,<sup>2,3)</sup> the configuration at C-23 and C-25 positions as well as the biological role of this metabolite are unknown yet. In order to confirm the reported structure and to elucidate the configuration at C-23 and C-25, it is necessary to synthesize four possible isomers. It would be also urged to prepare the natural caldiol lactone for biological investigation. We describe herein a synthesis of (23*R*)-caldiol lactone.

The 22-aldehyde 3-THP ether **1**<sup>4)</sup> derived from 22,23-bisnorcholeonic acid was coupled with vinylmagnesium bromide to give a mixture of the 22-alcohols (**2**) in a 6:1 ratio. The less polar major alcohol, mp 155–156°, possesses the 22*R*-configuration according to the precedents for this mode of reaction.<sup>5)</sup> The 22-alcohol **2** was reacted with ethyl orthopropionate and propionic acid as catalyst in refluxing xylene to give 22,23-*trans* 26-ethyl ester **3a** [mp 105–107.5°; NMR  $\delta$  1.11 ppm (3H, d,  $J=6.6$  Hz, 27-H<sub>3</sub>), 5.20–5.50 (3H, m, 6-H, 22-H, 23-H); IR 1720 cm<sup>-1</sup>] in 96% yield. The 26-ester **3a** was hydrolysed to the 3-hydroxy-26-acid **3b**, mp 175–178°, by HCl-methanol and then KOH-methanol treatment. Iodolactonization<sup>6)</sup> of the acid with iodine in acetonitrile at –0° gave regio- and stereoselectively a single product **4a** [mp 220–224°; 94% yield; NMR  $\delta$  1.28 (3H, d,  $J=6$  Hz, 27-H<sub>3</sub>), 2.50–3.10 (1H, m, 25-H), 4.10 (1H, dd,  $J=5.1, 5.7$  Hz, 22-H), 4.60 (1H, m, 1/2w, 30 Hz, 23-H); IR 1768 cm<sup>-1</sup>]. The iodolactone **4a** was then reduced by freshly distilled tributyltinhydride in dry THF at room temperature to the lactone **5a** [mp 223–224°; 85% yield; NMR  $\delta$  1.27 (3H, d,  $J=7.5$  Hz, 27-H<sub>3</sub>), 4.52 (1H, m, 1/2w 26 Hz, 23-H); IR 1760 cm<sup>-1</sup>; CD (dioxane)  $[\theta]^{20}$  (nm): –19 (249) (negative maximum).

- 1) Studies on Steroids, Part LXXI, Part LXX: M. Ishiguro, S. Takatsuto, M. Morisaki, and N. Ikekawa, *J.C.S. Chem. Comm.*, in press.
- 2) J.K. Wichmann, H.F. DeLuca, H.K. Schnoes, R.L. Horst, R.M. Shepard, and N.A. Jorgensen, *Biochem.*, **22**, 4755 (1979).
- 3) R.L. Horst, *Biochem. Biophys. Res. Comm.*, **89**, 286 (1979).
- 4) M. Ishiguro, H. Saito, A. Sakamoto, and N. Ikekawa, *Chem. Pharm. Bull.*, **26**, 3715 (1978).
- 5) M. Anastasia, A. Fiecchi, and A. Sala, *J.C.S. Chem. Comm.*, **1979**, 858.
- 6) P.A. Bartlett and J. Myerson, *J. Am. Chem. Soc.*, **100**, 3950 (1978).

The C-23 configuration of the lactone **5a** was determined as *R* by transformation of the compound **4a** into 22- and 23-hydroxycholesterols as follows. The iodolactone 3-THP ether **4b** was converted to 22,23-epoxy-26-methyl ester **6** (mp 184–185°) with sodium carbonate in methanol. Reduction of the ester with  $\text{LiAlH}_4$  in THF at room temperature gave 22,23-epoxy-26-ol **7a**. After iodination of the 26-ol by treatment with  $\text{TsCl}$ -pyridine and then  $\text{NaI}$ -acetone (reflux), the iodide **7b** was reduced with tributyltinhydride to 26-methyl compound **7c**. Reduction of the epoxide with  $\text{LiAlH}_4$  and subsequent removal of the 3-THP group afforded a 1:1 mixture of 22- and 23-hydroxycholesterols. These hydroxycholesterols were identical with the authentic samples of (22*R*)-22-hydroxycholesterol (**8**)<sup>7)</sup> and (23*S*)-23-hydroxycholesterol (**9**),<sup>8)</sup> respectively, with respect to the retention times on GLC<sup>9)</sup> and HPLC.<sup>10)</sup>

Introduction of a hydroxy group at C-25 position was achieved by oxidation with  $\text{MoOPH}$  ( $\text{MoO}_5 \cdot \text{Py} \cdot \text{HMPA}$ ) of the enolate of lactone generated by lithium diisopropylamide<sup>11)</sup> in THF at  $-78^\circ$  to give 25-hydroxy-lactone **10a** [mp 184–193°, 65% yield; NMR  $\delta$  1.47 (3H, s, 27- $\text{H}_3$ );




Chart 1

- 7) E.P. Burrows, G.M. Hornby, and E. Caspi, *J. Org. Chem.*, **34**, 103 (1969).
- 8) J.E. van Lier and L.L. Smith, *J. Pharm. Sci.*, **59**, 719 (1970).
- 9) The retention times on GLC using glass capillary column, 30 m  $\times$  0.25 mm i.d.; (22*R*)-22-OH (**8**) bis-trimethylsilyl ether (TMSi), 37.11 min; (22*S*)-22-OH bis-TMSi, 38.11 min; (23*R*)- and (23*S*)-23-OH (**9**) bis-TMSi, 41.22 min.
- 10) The retention times on HPLC using Zorbax SIL, 15 cm  $\times$  4.6 mm i.d., hexane- $\text{CH}_2\text{Cl}_2$  (6:1), 20 kg/cm<sup>2</sup>; (22*R*)-22-OH (**8**) bis-(+)- $\alpha$ -methoxy- $\alpha$ -trifluoromethyl-phenylacetate (MTPA), 7.4 min; (22*S*)-OH bis-MTPA, 9.0 min; (23*R*)-23-OH bis-MTPA, 9.4 min; (23*S*)-23-OH (**9**) bis-MTPA, 7.8 min.
- 11) E. Vedejs, D.A. Engler, and J.E. Telschow, *J. Org. Chem.*, **43**, 188 (1978).

IR 1762  $\text{cm}^{-1}$ ; CD (dioxane)  $[\theta]^{20}$  (nm)  $-49510$  (230) negative maximum<sup>12)</sup>] as a single product. After conversion of the 3-THP ether to 3-acetate, transformation of **10b** (mp 224—228°) into calcidiol lactone **12** was carried out by the standard procedure.<sup>13)</sup> Bromination with N-bromosuccinimide in  $\text{CCl}_4$ , followed by debromination (collidine in refluxing xylene) gave a mixture of the 5,7-diene and 4,6-diene. Treatment with *p*-toluenesulfonic acid to convert the 4,6-diene into the much less polar 2,4,6-triene, purification by preparative TLC, alkaline hydrolysis of the acetyl group and then acidification gave the 5,7-diene **11** (30% yield,  $\lambda_{\text{max}}$  262, 271, 281.5 and 293 nm). Irradiation of the diene **11** with a medium pressure mercury lamp in benzene-EtOH solution at 0° for 2.5 min, refluxing for 1 hr in the same solvent and purification by preparative TLC afforded the (23*R*)-calcidiol lactone **12** [23% yield,  $\lambda_{\text{min}}$  226,  $\lambda_{\text{max}}$  265 nm; MS *m/e*: 428 ( $\text{M}^+$ ), 410, 395, 369, 271, 253, 211, 199, 197, 183, 171, 159, 158, 143, 136, 118]. The UV and MS spectra of the synthetic calcidiol lactone were superimposable with the data reported by DeLuca.<sup>2)</sup> The signals in NMR spectrum [ $\text{CDCl}_3$ , 200 MHz;  $\delta$  0.58 (3H, s, 18- $\text{H}_3$ ), 1.05 (3H, d,  $J=5$  Hz, 21- $\text{H}_3$ ), 3.99 (1H, m, 3 $\alpha$ -H), 4.86 and 5.10 (2H, s pair of broad s, 19-H), 6.07 (1H, d,  $J=12$  Hz, 7-H), 6.28 (1H, d,  $J=12$  Hz, 6-H) are almost identical with the data reported for the natural metabolite, except one proton signal at  $\delta$  4.78(m) corresponding to C-23 proton, instead of the signal at  $\delta$  4.46.<sup>2)</sup> This might suggest that the natural calcidiol lactone has 23*S*-configuration. However, it cannot be ruled out that this shift may be due to the difference of the C-25 stereochemistry.

**Acknowledgement** We thank Dr. S. Urano, Tokyo Metropolitan Institute of Gerontology, for the 200 MHz NMR spectra. This work was supported by a Grant-in-Aid from Ministry of Education.

Laboratory of Chemistry for Natural  
Products, Tokyo Institute of  
Technology,  
Nagatsuta, Midori-ku,  
Yokohama 227, Japan

NOBUO IKEKAWA  
YUTAKA HIRANO  
MASAJI ISHIGURO<sup>14)</sup>  
JUN-ICHI OSHIDA  
TADASHI EGUCHI  
SATORU MIYASAKA

Received July 21, 1980

- 12) The CD spectrum also supported the configuration at C-23; cf. S. Uyeo, J. Okada, S. Matsunaga, and J.W. Rowe, *Tetrahedron*, **23**, 2859 (1968); F.H. Allen, J.P. Kutney, J. Trotter, and N.D. Westcott, *Tetrahedron Lett.*, **1971**, 283; J.A. Edwards, J. Sundeen, W. Salmond, T. Iwadare, and J.H. Fried, *ibid.*, **1972**, 791.  
13) J. Oshida, M. Morisaki, and N. Ikekawa, *Tetrahedron Lett.*, **21**, 1755 (1980).  
14) Present address: *Suntory Institute for Biomedical Research, Suntory Ltd., Wakayamadai, Shimamoto-cho, Mishima-gun, Osaka.*